Search | Clinical Trials Finder

Conditions: Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Interventions: AZD3427, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more

Conditions: Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
Interventions: PEG -Intron, Colchicine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more

Conditions: Chronic Low Back Pain, Osteoarthritis
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more

Conditions: Alcohol Use Disorder, Mental Health Disorder
Interventions: Integrating Combined Therapies, Standard Care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rutland, Vermont

Conditions: Healthy
Interventions: Mirikizumab - IV, Mirikizumab - SC, Placebo - IV, Placebo - SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: Lutikizumab Dose A, Lutikizumab Dose B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cypress, California • Grayslake, Illinois • Austin, Texas

Conditions: Contraception
Interventions: Depot-Medroxyprogestereone Acetate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: PF-08653944; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • Tampa, Florida

Conditions: Bioequivalence
Interventions: efgartigimod PH20 SC as a prefilled syringe presentation, efgartigimod PH20 SC as a vial + syringe presentation; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab, placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 78
States / cities: Coronado, California • Irvine, California • La Jolla, California + 60 more

Conditions: Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions: AMG 397, Dexamethasone, Azacitidine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more

Conditions: Non Small Cell Lung Cancer
Interventions: CMP-001, Atezolizumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions: Lepodisiran Sodium, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 17,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more

Conditions: Healthy Subjects
Interventions: ILV-095, Placebo; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HER2-positive Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Beverly Hills, California • San Francisco, California • Stanford, California + 9 more

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions: Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Melphalan; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Ixazomib; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions: rhIGF-1 (mecasermin) for a period of 86 weeks; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 3 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Coronary Disease
Interventions: RUC-4 Compound; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes, Neuropathy, Impaired Glucose Tolerance
Interventions: lifestyle modification; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions: Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 287
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 58
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Schizophrenia
Interventions: TV-44749, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 38 more

Conditions: Psoriasis
Interventions: Risankizumab, Autoinjector; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Search by objective public record fields.

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Integrating Combined Therapies for Persons With Co-occurring Disorders

A Study of Mirikizumab (LY3074828) in Healthy Participants

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients

A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

Improving Autonomic Function and Balance in Diabetic Neuropathy

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis